Huasun(SZ:000790)2025-04-28 14:00Financial Performance - The company's operating revenue for 2024 was ¥863,976,571.55, a decrease of 13.89% compared to ¥1,003,376,637.04 in 2023[22] - The net profit attributable to shareholders for 2024 was -¥6,690,166.26, representing a decline of 124.19% from ¥27,659,463.93 in the previous year[22] - The net profit after deducting non-recurring gains and losses was -¥15,563,890.23, down 143.94% from ¥35,421,382.66 in 2023[22] - The basic earnings per share for 2024 was -¥0.01, a decrease of 125.00% from ¥0.04 in 2023[22] - The weighted average return on net assets was -0.65%, down from 2.72% in the previous year[22] - The company reported a significant decline in both net profit and revenue, indicating potential challenges in its operational performance[22] - In Q1 2024, the company reported revenue of approximately ¥179.28 million, which increased to ¥278.56 million in Q2, but decreased to ¥205.24 million in Q3 and ¥200.90 million in Q4[26] - The net profit attributable to shareholders was ¥2.28 million in Q1, rising to ¥6.83 million in Q2, but turned negative with a loss of ¥3.37 million in Q3 and ¥12.43 million in Q4[26] - The total revenue for 2024 was approximately ¥863.98 million, representing a decrease of 13.89% compared to ¥1,003.38 million in 2023[61] Cash Flow and Assets - The net cash flow from operating activities increased by 35.57% to ¥64,278,831.37, compared to ¥47,414,104.46 in 2023[22] - Total assets at the end of 2024 reached ¥2,249,238,967.54, an increase of 5.43% from ¥2,133,478,855.05 at the end of 2023[22] - The net assets attributable to shareholders decreased by 0.71% to ¥1,025,895,578.65 from ¥1,033,194,655.74 in 2023[22] - The total cash inflow from financing activities increased by 38.94% to ¥680,067,649.83 in 2024, up from ¥489,464,280.26 in 2023[76] - The company's total assets included cash and cash equivalents of ¥209,467,279.68, accounting for 9.31% of total assets at the end of 2024[78] Government Support and Non-Recurring Gains - The company received government subsidies amounting to ¥5.63 million in 2024, up from ¥3.98 million in 2023, indicating a positive trend in government support[27] - The total non-recurring gains and losses for 2024 amounted to approximately ¥8.87 million, a significant recovery from a loss of ¥7.76 million in 2023[27] Market and Product Development - The pharmaceutical manufacturing industry in China is projected to maintain a revenue of ¥2.53 trillion in 2024, with a slight profit decline of 1.1%[30] - The company anticipates further market expansion and product innovation in response to the evolving healthcare landscape and consumer demands[30] - The health beverage market is expected to grow from ¥190 billion in 2019 to ¥310 billion by 2025, driven by health trends and innovative products[34] - The company has established a three-tier collaborative marketing network covering various regions in China, focusing on cardiovascular, ENT, and pediatric respiratory diseases, enhancing its competitive edge in these specialized treatment areas[35] - The core product, Sanqi Tongshu Capsule, was selected for the National Traditional Chinese Medicine Procurement Alliance in 2024 and is recommended in the "Guidelines for the Prevention and Treatment of Stroke with Integrated Traditional Chinese and Western Medicine (2023 Edition)"[35] Research and Development - The company has applied for and acquired a total of 203 patents, with 168 authorized patents, including 4 international invention patents[47] - The company is advancing the development of a new product, Sanqi Tongshu Capsule, aimed at enhancing clinical value and market presence[73] - The number of R&D personnel increased to 166 in 2024, representing a growth of 23.88% compared to 134 in 2023[75] - R&D investment amounted to ¥28,178,452.75 in 2024, a decrease of 11.67% from ¥31,902,380.11 in 2023[75] Operational Efficiency and Management - The organization implemented a flat management structure to enhance operational efficiency, focusing on customer needs and market-driven strategies[59] - The company plans to strategically divest its steel structure business to concentrate resources on the core pharmaceutical industry[57] - The company has established a financial management center with a strict accounting system, ensuring independent financial decision-making without interference from shareholders[122] - The company has a complete internal management structure that operates independently from controlling shareholders[121] Environmental Management - The company has implemented strict environmental management practices, including obtaining necessary pollution discharge permits[169] - The pharmaceutical factory has been designated as a key wastewater discharge unit for 2024 in Chengdu, and has actively improved its environmental management level[172] - The company invested approximately 1.66 million yuan in environmental protection in 2024, covering clean production audits, online monitoring, and wastewater treatment operations[174] Shareholder Relations and Governance - The company held its first temporary shareholders' meeting in 2024 with a participation rate of 17.95% on January 31, 2024[123] - The company is committed to maintaining the legal rights of all shareholders through diligent board practices[143] - The board of directors approved a new compensation structure for executives, with an average increase of 15% in salaries[136] - The company has engaged in various investor relations activities to discuss business development and operational strategies throughout the reporting period[107] Strategic Commitments - The company has committed to avoiding any new competitive business activities with the listed company for a period of 5 years following the acquisition completion[182] - The company will take comprehensive measures, including asset injection and restructuring, to mitigate any potential adverse effects on the listed company due to overlapping business operations[182] - The company has pledged to avoid related party transactions with Taihe Health and its subsidiaries, ensuring fair and reasonable pricing[183]